Tumors with high expression of PD-L1 represent 30% to 40% of all advanced NSCLC (60) and are highly sensitive to ICI provided there are no EGFR/ALK/ROS1 genetic alterations. Here, EGFR is linked to non-small cell lung carcinoma.